Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › Phase 2b

Phase 2b

Efinopegdutide · MASH F2–F3

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Efinopegdutide
Population
MASH F2–F3
Official title
A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)
Sponsor
Merck Sharp & Dohme LLC
Phase
Phase 2
Registry status
completed · 2023-06 → 2025-12
Participants
386
Duration
52 weeks
Registry
NCT05877547

Outcomes in the indication

Phase 2b Efinopegdutide · MASH F2–F3 · 52 weeks · n = 386 abstract

MASH resolution without worsening of fibrosis +43.0 / +49.5 / +47.8 percentage points vs placebo (4 / 7 / 10 mg); fibrosis improvement +21.7 / +30.4 / +13.0 (10 mg not significant). Open-label semaglutide 2.4 mg arm: 53 % and 25 %.

MeasureDrugControlDifference (95 % CI)Status
MASH resolution without worsening of fibrosis 4 mg
week 52
+56.0+13.0+43.0 (+25.7 to +57.8) percentage pointsabstract
MASH resolution without worsening of fibrosis 7 mg
week 52
+63.0+13.0+49.5 (+31.4 to +64.2) percentage pointsabstract
MASH resolution without worsening of fibrosis 10 mg
week 52
+61.0+13.0+47.8 (+30.7 to +62.0) percentage pointsabstract
Fibrosis improvement (≥1 stage) without worsening of steatohepatitis 4 mg
week 52
+43.0+21.0+21.7 (+7.1 to +35.7) percentage pointsabstract
Fibrosis improvement (≥1 stage) without worsening of steatohepatitis 7 mg
week 52
+52.0+21.0+30.4 (+15.4 to +44.3) percentage pointsabstract
Fibrosis improvement (≥1 stage) without worsening of steatohepatitis 10 mg
week 52
+34.0+21.0+13.0 (−1.2 to +26.8) percentage pointsabstract
Verbatim quotes (6)
  • MASH resolution without worsening of fibrosis
    difference vs placebo 43·0 percentage points [95% CI 25·7 to 57·8; p<0·0001] for 4 mg, 49·5 percentage points [31·4 to 64·2; p<0·0001] for 7 mg, and 47·8 percentage points [30·7 to 62·0; p<0·0001] for 10 mg
  • MASH resolution without worsening of fibrosis
    difference vs placebo 43·0 percentage points [95% CI 25·7 to 57·8; p<0·0001] for 4 mg, 49·5 percentage points [31·4 to 64·2; p<0·0001] for 7 mg, and 47·8 percentage points [30·7 to 62·0; p<0·0001] for 10 mg
  • MASH resolution without worsening of fibrosis
    difference vs placebo 43·0 percentage points [95% CI 25·7 to 57·8; p<0·0001] for 4 mg, 49·5 percentage points [31·4 to 64·2; p<0·0001] for 7 mg, and 47·8 percentage points [30·7 to 62·0; p<0·0001] for 10 mg
  • Fibrosis improvement (≥1 stage) without worsening of steatohepatitis
    difference vs placebo 21·7 percentage points [7·1 to 35·7; p=0·0038] in the efinopegdutide 4 mg group, 30·4 percentage points [15·4 to 44·3; p<0·0001] in the efinopegdutide 7 mg group, and 13·0 percentage points [-1·2 to 26·8; p=0·072] in the efinopegdutide 10 mg group
  • Fibrosis improvement (≥1 stage) without worsening of steatohepatitis
    difference vs placebo 21·7 percentage points [7·1 to 35·7; p=0·0038] in the efinopegdutide 4 mg group, 30·4 percentage points [15·4 to 44·3; p<0·0001] in the efinopegdutide 7 mg group, and 13·0 percentage points [-1·2 to 26·8; p=0·072] in the efinopegdutide 10 mg group
  • Fibrosis improvement (≥1 stage) without worsening of steatohepatitis
    difference vs placebo 21·7 percentage points [7·1 to 35·7; p=0·0038] in the efinopegdutide 4 mg group, 30·4 percentage points [15·4 to 44·3; p<0·0001] in the efinopegdutide 7 mg group, and 13·0 percentage points [-1·2 to 26·8; p=0·072] in the efinopegdutide 10 mg group

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: Phase 2b. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/phase-2b/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.